P37 Humoral immunity to mRNA-based COVID-19 vaccines after a booster dose in patients with psoriasis receiving immunomodulatory therapy
Year: 2024
Type: article
Study design: Observational Study
Abstract: Short-term immunity after completing vaccination with mRNA-based COVID-19 vaccines is similar between patients with psoriasis receiving immunomodulatory therapy and healthy individuals. However, a faster decline of immunity 6 months after vaccination in patients receiving immunomodulatory therapy has been described. There is still limited data on long-term immunity to the vaccines and immunity after a booster dose. Here we present data on humoral responses 12 months after the initial vaccine programme and a booster dose in patients with psoriasis receiving MTX or biologics. This study was part of a prospective cohort study that included 123 patients with psoriasis who were receiving immunomodulatory therapy and 226 healthy controls. Humoral immunity to mRNA-based COVID-19 vaccines was measured by IgG level and antibody neutralizing capacity. Blood samples were collected before vaccination, 3 weeks after the first vaccine dose, and 2, 6, and 12 months after the first vaccine dose. All participants received an mRNA-based COVID-19 vaccine and two vaccine doses administrated at the standard interval recommended by the manufacturers. Data were analysed using a mixed effects model with the level of IgG or neutralizing capacity as the dependent variable, time of sampling and participant group as fixed effects, and participant ID as a random effect. At 12 months, data were available for 63 patients receiving the following treatments: anti-tumour necrosis factor-α (n = 24), anti-interleukin (IL)-17 (n = 5), anti-IL-12/23 (n = 16), MTX (n = 18), and 173 healthy controls. A booster vaccine dose was received by 95% of the patients and 94% of the controls before collecting the 12-month sample. Most patients (98%) and controls (98%) had a positive humoral response, a composite outcome of an IgG level and neutralizing capacity above defined thresholds. However, numeric IgG levels and neutralizing capacities were lower in patients than in controls. In patients, the predicted mean of IgG was 8512 AU/mL, 95% confidence interval (CI) 5835–12 418 compared with 15 029 AU/mL, 95% CI 12 130–18 620 in controls (P < 0.001). For neutralizing capacity, the predicted mean was 95% inhibition, 95% CI 89–100 in patients vs. 99% inhibition, 95% CI 97–100 in controls (P < 0.001). Similar, positive humoral responses were found in patients with psoriasis receiving immunomodulatory therapy and control 12 months after the initial vaccine programme and a booster dose. Levels of IgG and neutralizing capacity increased in both groups after receiving the booster vaccine. However, the numeric level of IgG and neutralizing capacity was lower in patients. It is currently unknown if the observed difference has clinical relevance.
Source: British Journal of Dermatology
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4405229619